Literature DB >> 6402184

Choosing treatment for metastatic breast cancer.

L A Price.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6402184      PMCID： PMC1546815          DOI： 10.1136/bmj.286.6365.643-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  4 in total

1.  Response of advanced breast carcinoma to the combination of the antimetabolite, Methotrexate, and the alkylating agent, thio-TEPA.

Authors:  E M GREENSPAN; M FIEBER; G LESNICK; S EDELMAN
Journal:  J Mt Sinai Hosp N Y       Date:  1963 May-Jun

2.  Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.

Authors:  H Glucksberg; S E Rivkin; S Rasmussen; B Tranum; N Gad-el-Mawla; J Costanzi; B Hoogstraten; J Athens; T Maloney; J McCracken; C Vaughn
Journal:  Cancer       Date:  1982-08-01       Impact factor: 6.860

3.  Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.

Authors:  M De Lena; C Brambilla; A Morabito; G Bonadonna
Journal:  Cancer       Date:  1975-04       Impact factor: 6.860

4.  Adjuvant chemotherapy of breast cancer.

Authors:  R G Cooper; J F Holland; O Glidewell
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.